All AbMole products are for research use only, cannot be used for human consumption.
10058-F4 inhibits the growth of leukemic cells and dimerization of the c-Myc/Max heterodimerization to control the cell proliferation, apoptosis, and differentiation, and its aberrant expression. 10058-F4 increased FOXO1 mRNA in MedB-1 cells. 10058-F4 is most efficient in inducing neuronal differentiation and lipid accumulation in MYCN-amplified neuroblastoma cells. 10058-F4 could markedly suppresse the wild-type LKB1 loss-induced cell invasiveness. 10058-F4 increased the chemosensitivity of HepG2 cells to low-dose doxorubicin, 5-fluorouracil and cisplatin.
Biochem Pharmacol. 2024 Feb 17;116065.
Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax
10058-F4 purchased from AbMole
Cells. 2022 Sep 3;11(17):2752.
Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia
10058-F4 purchased from AbMole
J Cell Mol Med. 2022 May;26(9):2646-2657.
Venetoclax enhances DNA damage induced by XPO1 inhibitors: A novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia
10058-F4 purchased from AbMole
Biomed Res Int. 2020 Jun 20;2020:9243681.
Shenmai Injection Supresses Glycolysis and Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant A549/DDP Cells via the AKT-mTOR-c-Myc Signaling Pathway
10058-F4 purchased from AbMole
 |
Source | J Transl Med (2014). Figure 2.10058-F4 |
| Method | apoptosis assay | |
| Cell Lines | HepG2 cells | |
| Concentrations | 100 or 130 μmol/l | |
| Incubation Time | 24 h | |
| Results | 10058-F4-induced growth inhibition is likely mediated by upregulation of p21 and indirect downregulation of cyclin D3. |
 |
Source | J Transl Med (2014). Figure 1.10058-F4 |
| Method | immunoblotting | |
| Cell Lines | HepG2 and Hep3B cells | |
| Concentrations | 100 μmol/l | |
| Incubation Time | 24 h | |
| Results | In HepG2 cells treated with10058-F4, there were no detectable binding of c-Myc protein to the E-box-containing oligonucleotides |
| Cell Experiment | |
|---|---|
| Cell lines | PC-3 and DU145 cells |
| Preparation method | MTT assay PC-3 cells (2 × 104 cells in logarithmic growth) were plated into 96-well culture plates and allowed to adhere to the plates for 24 h prior to the addition of 10058-F4 in medium containing 1% ethanol such that the final concentrations in the wells were 0.1-100 μM in medium containing 0.3% ethanol. After 72 h, 50 μl of 1 mg/ml MTT was added to each well. The cells were washed with medium and phosphate buffered saline, and 150 μl of DMSO was added to each well, followed by shaking for 5 min. The absorbance at 570 nm was read on DYNEX MRX Revelation microplate reader (Dynex, Vienna, VA, USA). Results were compared to wells containing cells treated with vehicle alone and were expressed as % inhibition. The IC50 was calculated using the Hill equation, the program ADAPT II, and data from three separate experiments. |
| Concentrations | 0.1-100 μM |
| Incubation time | 72 h |
| Animal Experiment | |
|---|---|
| Animal models | SCID mice bearing DU145 or PC-3 xenografts |
| Formulation | cremophor EL:ethanol:saline (1:1:8 v/v/v) at a final concentration of 2 or 3 mg/ml |
| Dosages | 20 or 30 mg/kg daily for 5 days for 2 weeks |
| Administration | i.v. |
| Molecular Weight | 249.35 |
| Formula | C12H11NOS2 |
| CAS Number | 403811-55-2 |
| Solubility (25°C) | DMSO 30 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[1] Müller I, et al. PloS one. Targeting of the MYCN Protein with Small Molecule c-MYC Inhibitors.
| Related c-Myc Products |
|---|
| 10074-G5
10074-G5 is a c-Myc/Max interaction inhibitor, which binds to a different specific binding site (region) of C-Myc than 10054-F4. |
| ML327
ML327 is a blocker of MYC, which mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition. |
| MYCi975
MYCi975 (Nuc-0200975) is an orally active MYC inhibitor that disrupts MYC/MAX interactions, promotes MYC T58 phosphorylation and MYC degradation, and impairs myC-driven gene expression. MYCi975 (NUC-0200975) has strong anti-tumor effect and good tolerance, increasing tumor immune cell infiltration and enhancing tumor sensitivity against PD1 immune studies. |
| APTO-253
APTO-253 (LOR-253) is a small molecule that inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. |
| IZCZ-3
IZCZ-3 is a potent c-MYC transcription inhibitor with antitumor activity. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
